Company intelligence / Profile preview

Shanghai Best-Link Bioscience LLC

Shanghai, Shanghai, Chinabestlinkbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Shanghai Best-Link Bioscience has several small molecule and nano-conjugate drug candidates in early-stage clinical development. Lead assets such as BL0175 and BL0020 are in Phase I trials targeting advanced solid tumors, including hormone receptor-positive cancers and pancreatic/small cell lung cancers. No late-stage or pivotal results have been reported yet; the company’s focus is on improving delivery efficiency and tumor penetration using its proprietary nanotechnology platforms[1][6][7].

Therapeutic areas: Oncology
Modalities: Small moleculesNano-conjugate drugsChemical drugs
Industry: Biotech

Drug pipeline

4 assets

BL0175

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shanghai Best-Link Bioscience LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Best-Link Bioscience LLC.

Explore the full profile